Objective-Sclerostin (SOST) has been identified as an important regulator of bone formation; however, it has not been previously implicated in arterial disease. The aim of this study was to assess the role of SOST in aortic aneurysm (AA) and atherosclerosis using human samples, a mouse model, and in vitro investigations. Approach and Results-SOST protein was downregulated in human and mouse AA samples compared with controls.
A ortic aneurysm (AA) and atherosclerosis are important causes of morbidity and mortality. Older age and smoking are important risk factors for cardiovascular disease, and one of the mechanisms by which they may promote vascular disease may be via stimulating epigenetic changes. [1] [2] [3] Although improvements have been made in the management of cardiovascular disease, there is a need to develop novel therapies to advance patient management.
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Sclerostin (SOST) is a secreted cysteine-knot protein expressed in bone, where it has been shown to control bone mineralization. 4, 5 SOST has no known function within human arteries; however, a recent study identified its expression within the aorta, suggesting that it may have a role in aortic diseases. 6 One of the major regulatory roles of SOST is inhibition of the canonical wingless-type mouse mammary virus integration site (Wnt) signaling pathway by binding to the transmembrane Wnt coreceptor low-density lipoprotein receptor-related proteins-4, -5, and -6. [7] [8] [9] Several studies have demonstrated a significant role for the Wnt signaling pathway in vascular development and remodeling. 10, 11 Traditionally, the canonical Wnt signaling pathway is activated when Wnt binds to its heterodimeric receptor complex (constituted by frizzled family proteins and low-density lipoprotein receptor-related proteins-5/6 coreceptor) located at the cell membrane, leading to a reduction of β-catenin degradation, increased translocation of β-catenin into the nucleus, and subsequent activation of Wnt target genes. 12, 13 Wnt/β-catenin signaling controls the expression of osteoprotegerin (OPG), osteopontin (OPN), and matrix metalloproteinase (MMP) -2, -7, and -9, which have all been implicated in aortic disease. [14] [15] [16] We hypothesized that SOST was differentially expressed in AA and played an important role in AA pathogenesis via regulation of the Wnt/β-catenin signaling pathway. We investigated this using human AA samples and an experimental model.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results
Sost Was Downregulated in the Aortas of Apolipoprotein E-Null Mice That Developed AA
Angiotensin II (AngII) infusion for 28 days in apolipoprotein E null (ApoE −/− ) mice results in AA formation; however, we and others have reported that this phenotype is not fully penetrant, and a small subset of these mice do not develop AA after AngII infusion. 17 Protein levels of Sost were analyzed in extracts of suprarenal aortas (SRA) from ApoE −/− mice that received AngII for 28 days. We analyzed 2 groups of mice. First, mice that developed marked SRA dilatation after AngII infusion (median SRA diameter 2.57 mm, interquartile range [IQR] 2.34-2.81; n=5) and, second, mice that developed minimal SRA dilatation after AngII infusion (median SRA diameter 1.06 mm, IQR 0.88-1.11; n=6). The SRA diameters of the second group were similar to those of mice that received saline infusion alone, as we have previously reported. 17 Sost protein was detected within the mouse aorta, and its expression levels were significantly reduced by ≈3-fold (P=0.004) in aortas of mice that developed marked SRA dilatation compared with aortas from mice that did not develop marked SRA dilatation after AngII infusion ( Figure 1A ). These observations suggested a negative correlation between Sost levels and AA formation and highlighted the relevance of the AngII-induced mouse model to further investigate the role of SOST in AA formation.
SOST Overexpression Protected ApoE −/− Mice From AA Formation
Given the significant reduction in aortic SOST expression observed in mouse AAs, we sought to determine whether SOST played a protective role against AA development using 2 approaches: (1) Figure 1B) .
We measured the diameters of the SRA and infrarenal aorta of 12-week-old SOST Tg .ApoE −/− (n=6) and ApoE −/− (n=6) mice using ultrasound and found these to be similar (Table I in the online-only Data Supplement). AngII infusion is a well-established method for the induction of AA and aortic rupture in mice. 19 AngII was subcutaneously infused into ApoE −/− (n=12) and SOST
Tg
.ApoE −/− (n=12) mice. In the control (ApoE −/− ) group, there were 4 deaths because of rupture of the aortic arch (rupture rate 33%) within the first week of starting the AngII infusion; however, there were no aortic ruptures in the mice carrying the human SOST transgene (P=0.028; Table II Figure 2A ). Mean diameters of the aortic arch and thoracic and infrarenal aorta segments were also smaller in SOST Tg .ApoE −/− mice (Table III in the online-only Data Supplement) .
In a further experiment, AngII was infused subcutaneously for 28 days in ApoE −/− mice (n=20) receiving vehicle control or daily rmSost protein injections (n=20). Three mice died because of aortic rupture in the rmSost-injected group (rupture rate 15%), and 5 mice died of aortic rupture in the saline-injected group (rupture rate 25%). All the ruptures occurred within the aortic arch (Table II in the online-only Data Supplement). The mean maximum SRA diameter of the rmSost-injected group (1.44±0.12 mm) was significantly smaller than that of the vehicle control group (2.06±1.44 mm; P=0.004; Figure 2B ). Mean diameters of the aortic arch and thoracic and infrarenal aorta segments were also smaller in mice receiving rmSost (Table III  in Figure 2C ).
Systemic inflammation was assessed by a cytometric bead assay to evaluate the concentrations of 6 inflammatory markers previously implicated in atherosclerosis and AA formation. 22 23, 24 We, therefore, examined the role of SOST in protecting against aortic ECM degradation. As expected, hematoxylin and eosin staining showed marked thickening of the aortic wall with extensive matrix remodeling and degradation in AngII-infused ApoE −/− mice ( Figure 3A , i). AngIIinfused ApoE −/− mice also showed large SRA lumen diameters consistent with the morphometry findings discussed earlier. Figure 3D ).
Assessment of picrosirius red staining for collagen within the SRA tissue by polarization microscopy was performed to further assess collagen distribution in AngII-induced AA. Under polarized light, disrupted collagen distribution and orientation was found within picrosirius-stained SRA sections from ApoE 
SOST Protected AngII-Infused ApoE −/− Mice From Macrophage Infiltration
Localization of macrophages by immunohistochemistry showed a significantly higher staining area for macrophages , apolipoprotein E deficient; IRA, infrarenal aorta; rmSost, recombinant mouse sclerostin protein; SOST, sclerostin; SRA, suprarenal aorta; and TA, thoracic aorta. 
SOST Overexpression Is Associated With Reduced Aortic Expression of Genes Implicated in AA
Matrix degradation and calcification are important pathological changes commonly observed in end-stage human AA tissues. Several genes that control these pathological processes, such as MMP-9, OPN (Spp1), and OPG (Tnfrsf11b), have been reported to be differentially regulated by the Wnt pathway. [25] [26] [27] [28] We assessed the relative gene expression of Mmp-9, Spp1, and Tnfrsf11b in SRA samples obtained from mice infused with AngII for 28 days. Quantitative reverse transcriptase polymerase chain reaction showed that the median relative mRNA levels of Mmp-9, Tnfrsf11b, and Spp1 were significantly decreased in SOST Tg .ApoE −/− and in rmSostreceiving mice compared with ApoE −/− controls ( (Table 2) .
Wnt/β-Catenin Signaling Pathway Is Activated in AngII-Induced AA
SOST is an inhibitory molecule of the Wnt/β-catenin signaling pathway 7 ; therefore, we examined the expression of the major signaling molecule of the Wnt pathway in mice SRA samples. The Wnt signaling pathway is regulated by glycogen synthase kinase (GSK)-3β activity. 24 Nonphosphorylated GSK-3β phosphorylates β-catenin, leading to its degradation and inhibition of Wnt signaling. Phosphorylation of Gsk-3 β leads to stabilization of β-catenin and activation of the Wnt pathway. We observed an ≈2-fold higher phospho-GSK-3β: total GSK-3β ratio in SRA samples from mice that developed AA (median 0.77 AU, IQR 0.41-1.14; n=4) compared with those that did not develop AA after AngII infusion (median 0.26, IQR 0.22-0.33; P=0.009; n=6), suggesting that Wnt signaling was activated in AngII-induced AA ( Figure 4C , i and ii).
We assessed GSK-3β activity (expressed as phosphor-GSK-3β:total GSK-3β ratio) in SRA samples from ApoE Figure 4E , i and ii). This result suggests that Akt signaling was not relevant to the ability of SOST to limit AA.
SOST Is Downregulated and the Wnt/β-Catenin Signaling Pathway Is Activated in Human AA
We examined the levels of SOST protein expression in biopsies of human AA and those from normal abdominal aortas of organ donors. Western blotting analysis revealed that SOST protein expression was significantly lower in the AA tissues (n=6) relative to control samples from organ donor tissues (P=0.008; n=6). A similar decrease in SOST protein staining was also observed by immunohistochemistry in the AA body biopsies (n=6) compared with the relative normal AA neck biopsies (n=6). Immunohistochemistry of cryostat sections demonstrated the presence of VSMCs expressing SOST within the AA neck biopsies. Dense accumulation of SOST-expressing cells was observed within the media and the adventitia within all AA neck biopsies assessed ( Figure 5B, i) . In contrast, relatively sparse presence of SOST-expressing cells was observed within media or adventitia of AA body biopsies ( Figure 5B , ii). Analysis of median relative SOST mRNA expression in AA body tissue (0.29, IQR 0.21-2.84; n=8) showed a nonsignificant decrease compared with AA neck biopsies (1.24, IQR 0.37-4.58, P=0.494; n=8). We also examined the median relative expression of β-catenin (CTNNB1) mRNA in the AA body and neck biopsies. A significantly increased median relative expression of the CTNNB1 gene (1.31, IQR 1.06-1.64; n=8) was found in the AA body compared with AA neck biopsies (0.97, IQR 0.86-1.26; P=0.049; n=8; Figure 5C ).
SOST Is Epigenetically Silenced in Human AA
SOST gene expression has previously been shown to be linked to the average levels of DNA methylation across the cytosine-phosphate-guanine (CpG) islands located in its proximal promoter. 30, 31 Hence, we assessed the levels of CpG island methylation in the promoter region of SOST in human aortic DNA samples. The SOST promoter region, which was assessed, included 17 CpG sites, of which 5 did not pass the quality assessment ( Figure 6A , i-iii). The methylation data obtained from the remaining 12 sites were used for subsequent analyses. We identified that the AA samples analyzed showed hypermethylation of all CpG sites analyzed, with an overall higher percentage of methylation in AA (mean±SEM=79.23±1.39%; n=32) relative to control biopsies (mean±SEM=61.33±2.34%; P<0.0001; n=32), suggesting that in AA, SOST is epigenetically silenced ( Figure 6B ).
Epigenetically Silenced SOST in Human VSMC Can be Reactivated
To investigate the role of DNA methylation in transcriptional silencing of the SOST gene promoter, we examined the effect of DNA methyl transferase inhibitor 5-azacytidine Figure 6C , ii).
Discussion
SOST is a potent inhibitor of bone mineralization, but little is known about its role in the vasculature. 32 In this study, we provide evidence that SOST protects the aorta from AA and atherosclerosis and that epigenetic silencing of SOST may promote aortic diseases.
SOST is known to be an important inhibitor of the Wnt/β-catenin pathway, and we provide evidence that this pathway is upregulated in mouse and human AA. The Wnt/β-catenin pathway has previously been reported to control the expression of the bone proteins OPG and OPN. 25, 26 OPN is a secreted highly phosphorylated sialoprotein, which is a prominent component of the mineralized ECM, and we previously reported an association between high serum concentrations of OPN and AA. 33 OPN promotes inflammation 34 and is also involved in the activation of proteolytic pathways, including an increase in pro-MMP-9 activity. 35 OPN deficiency limits AA development in the AngII mouse model. 36 OPG is a secreted glycoprotein member , apolipoprotein E deficient; GSK, glycogen synthase kinase; NS, not significant; rmSost, recombinant mouse sclerostin protein; SOST, sclerostin; and SRA, supra renal aorta.
of the tumor necrosis factor receptor superfamily 37 and is expressed by a variety of cell types, including VSMCs, endothelial cells, dendritic cells, and lymphocytes. 38, 39 OPG concentration within the aortic wall is positively associated with established markers of AA severity and pathogenesis, 40 and higher circulating OPG concentrations have been reported in AA patients and found to be positively associated with AA progression. 41, 42 OPG promotes an inflammatory phenotype in aortic VSMCs through upregulation of cathepsin S, MMP-2, and MMP-9. 43 OPG deficiency protects against AngII-induced AA and aortic rupture. 43 We found that upregulation of SOST downregulated OPN and OPG within mouse aortas, suggesting that inhibition of the Wnt pathway because of SOST protected from AA as a result of downregulating these proaneurysmal genes. AngII has been reported to play a crucial role in several vascular pathologies, including AA and atherosclerosis. 44, 45 AngII infusion is reported to promote aneurysm formation in both the thoracic and abdominal aorta in mice. 19, 21, 46, 47 Our animal model studies suggest that SOST inhibits AngII-induced AA in both the thoracic and abdominal aorta and also inhibits AngII-induced atherosclerosis. (ii) Blots were quantified and analyzed by densitometry, and the ratio of SOST was normalized to β-actin. Quantification graph shows data presented as median and interquartile ranges (whiskers). B, Representative low power (×100) photomicrographs of immunohistochemical staining of SOST protein in cryostat sections obtained from biopsy samples of (i) relatively normal AA neck and (ii) diseased AA body. The section from the AA neck biopsy illustrates a relatively well-maintained elastic media with minimal infiltration of the adventitia by inflammatory cells. Intense SOST protein staining is observed in the medial region with mild staining in the adventitial region. In contrast, the biopsy from the body of the AA has marked medial elastin degradation and infiltration of the adventitia by inflammatory cells with minimal staining for SOST protein. Scale bar: 50 μm. C, Expression of the CTNNB1 within AA neck and AA body biopsies. Quantification graph depicts increased expression of CTNNB1 within AA body biopsies compared with AA neck biopsies (n=8/group, P=0.049 calculated with nonparametric Mann-Whitney U test). Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for relative gene expression. AA indicates aortic aneurysm; CLT, control; CTNNB1, β-catenin gene; and SOST, sclerostin gene. Consistent with previous findings, 44, 48 AngII infusion for 28 days elevated the systemic levels of inflammatory cytokines in ApoE −/− mice. The levels of inflammatory cytokines, such as monocyte chemoattractant protein-1, interleukin-6, tumor necrosis factor-α, and interferon-γ, were found to be significantly decreased in SOST Tg .ApoE −/− mice, and a similar but nonsignificant trend was observed in AngII-infused ApoE −/− mice administered rmSost. The decrease in inflammatory cytokines together with the reduction in macrophages within the aortic wall assessed by immunohistochemistry suggests that Wnt pathway suppression mediated by SOST limited both systemic and aortic wall inflammation. TGF-β1 has been reported to inhibit AngII-induced AA, and SOST has been found to be linked with TGF-β1. 49, 50 Plasma concentrations of total and active TGF-β1 were similar in mice with and without SOST upregulation, suggesting that there was unlikely to be an important effect of SOST on TGF-β1 in the mouse models studied.
Collagen limits vessel distension, while elastin contributes to arterial elasticity. During AA development, collagen and elastin gradually fragment and degrade, eventually leading to increased aortic stiffness and decreased strength. 51, 52 VSMCs are crucial structural support elements and are the major source of elastin and collagen. Under pathological conditions, such as AA, VSMCs undergo phenotypic switching and release MMPs, which results in ECM degradation. Dysfunction and depletion of VSMCs directly promotes AA. We found that SOST Tg .ApoE −/− and ApoE −/− mice receiving rmSost showed well-preserved aortic architecture with intact elastin fibers and collagen after 28 days of AngII infusion. Previous reports suggest that activation of canonical Wnt pathway stimulates fibrosis in vivo and in vitro. 53 Furthermore, previous in vitro observations in primary chondrocytes and mouse dermal fibroblasts suggest that SOST-mediated Wnt/β-catenin pathway inhibition is crucial in regulating expressions of various ECM-regulating genes and, thereby, preserving the aorta structure. 54, 55 We report that SOST is downregulated and the Wnt/β-catenin signaling pathway activated in AA. Our observation is supported by a recent microarray study, which reported that Wnt/β-catenin signaling and several Wnt/β-catenin pathway target genes were upregulated in the arterial intima and media during aging, which is an important risk factor for AA and atherosclerosis. 56 Studies also suggest that canonical Wnt signaling promotes mammalian aging and aging-related phenotypes, 57, 58 suggesting a mechanistic link between Wnt signaling and cardiovascular disorders in the elderly. 11 In addition, inhibition of Gsk-3β by lithium has been shown to activate Wnt pathway and promote endothelial cell senescence. 59 It is also evident from previous reports that during arterial aging, VSMCs switch from a proliferative response to nonproliferative response after Wnt/β-catenin activation. 56 It is also noteworthy that the proliferative response to β-catenin activation is abolished in VSMCs from old animals, as well as in in vitro aged VSMCs. 56 This suggests that VSMCs in the vessels of elderly subjects may not proliferate efficiently in response to β-catenin activation, favoring AA formation. 60 This could explain to some extent the role of SOST in AA, where downregulation of SOST might promote the senescent phenotypes of arterial cells.
Several factors such as aging and risk factors such as smoking may promote epigenetic silencing of genes in AA. 1, [61] [62] [63] Several lines of evidences suggest an important role of altered epigenetic status in inflammation, proliferation, and remodeling processes, which are also associated with the development of AA, indicating that epigenetic changes may play an important role in AA pathogenesis 1 ( Figure 6D ). Covalent addition of methyl groups at the 5′ position of cytosines within CpG nucleotides in the gene promoter is a major mechanism of epigenetic regulation and silencing of transcription. 64, 65 We assessed the DNA methylation levels in AA tissues compared with controls, showing that SOST promoter is hypermethylated in AA. Our study is supported by previous studies showing that the CpG island in the SOST promoter region is regulated by DNA methylation 31, 66 and plays an important role in the transcriptional regulation of the SOST gene. 67 Recent in vitro studies reported that methylation of CpG sites impaired nuclear-binding protein and lead to ≈75% inhibition of SOST promoter activity in human osteocyte cells. 31, 66 Intraluminal thrombus has been suggested as important in AA pathogenesis. 68, 69 Our in vitro studies showed that incubation of VSMCs with AA thrombus-conditioned media led to downregulation of SOST mRNA expression and upregulation of CTNNB1 mRNA expression. Incubation of VSMCs with 5-Aza resulted in the upregulation of SOST expression and concomitant downregulation of CTNNB1, suggesting that epigenetic regulation of SOST might be involved in the regulation of Wnt pathway target RT-PCR analysis was performed using gene-specific primers. The graph shows gene expression of (i) SOST and (ii) CTNNB1, relative to GAPDH expression (n=6/group). Statistical significance shown as *P<0.05 and **P<0.01. D, Working model of SOST action in AA pathogenesis. Epigenetic alteration leads to the silencing of SOST gene. When active, SOST binds to Wnt coreceptor low-density lipoprotein receptor-related proteins (LRP)5/6 to inhibit Wnt1 class signaling. Wnt interacts at the cell surface with frizzled receptor (Fzd) and lowdensity lipoprotein receptor-related 5/6 (LRP5/6). In the cytoplasm, β-catenin binds to the complex containing kinases, such as Gsk3-β casein kinase-1, which phosphorylates specific amino acids on the β-catenin. In the absence of Wnt, β-catenin is in a steady state, and free β-catenin is eventually degraded by 26S proteasome. Activation of Wnt signaling releases the β-catenin from the binding proteins, inhibits its phosphorylation, increases the cytoplasmic levels, and eventually promotes its nuclear translocation. After the nuclear translocation, β-catenin interacts with transcriptional factors, initiating the expression of several target genes. When SOST promoter undergoes inactivation because of DNA methylation, it results in the activation of Wnt signaling, promoting atherosclerosis, inflammation, and ECM degradation, promoting AA formation. Red arrows show activated pathway and blue shows inhibition. AA indicates aortic aneurysm; CLT, control; CpG, cytosine-phosphate-guanine; CTNNB1, β-catenin gene; ECM, extracellular matrix; GSK, glycogen synthase kinase; P, phosphorylation; SOST, sclerostin; TF, transcription factor; and Ub, ubiquitination.
gene expression. In vitro demethylation by 5-Aza resulted in an ≈3-fold increase in SOST mRNA expression in the human aortic VSMCs. This observation is similar to a previous report of human osteoblastic cell MG-63. 66 Our observation in AA biopsies and in vitro data together suggest that epigenetic downregulation of SOST is an important event in AA pathogenesis.
It is currently thought that the methylation pattern is stably maintained in fully differentiated cells; however, compared with other epigenetic modifications, DNA methylation patterns can change in adult cells, leading to altered gene expression and also potentially contributing to many diseases. 1, 63, [70] [71] [72] Recently, cigarette smoking was shown to activate polycomb machinery to repress a Wnt signaling antagonist DKK-1 (dickkopf WNT signalling pathway inhibitor 1) in lung cancer cells, suggesting that additional genes in the Wnt pathway may be epigenetically silenced in AA. 73 Epigenetic processes are potentially reversible, and several epigenetic drugs are currently being evaluated for the treatment of various diseases. 1 It may also be possible to safely modulate the epigenetic machinery by exogenous factors, such as improved nutrition and positive lifestyle modification. 1, 61, 62 This study has several strengths and limitations. The research incorporated 2 mouse models, in vitro and human tissue studies, which all suggested that SOST may be important in limiting AA and atherosclerosis. However, the effects of rmSost injection were less marked than those of transgenic upregulation of SOST, most likely because the degree of upregulation achieved was less marked and transient. However, we did not measure the levels of circulating rmSost. Another limitation of this study is that we did not have corresponding mRNA to assess the relative SOST gene expression in the human control and AA tissues in which DNA methylation was assessed. Ideally, the tissues obtained from the same patient should be analyzed for DNA methylation pattern and the specific mRNA abundance, but this was not possible.
Our findings suggest that SOST upregulation could be a potential means to inhibit AA and atherosclerosis in patients. It should be noted though that exogenous SOST administration could promote osteoporosis. In fact, SOST blocking treatments are being investigated for the treatment of osteoporosis. 74, 75 It is possible that such treatments will promote AA and atherosclerosis, and thus, patients should be carefully monitored for these complications.
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Conclusion
The present study shows that epigenetic inactivation of SOST seems to be present in human AA. Our study provides new insights into the role of SOST in the pathogenesis of AA and atherosclerosis. We show here that SOST plays a protective role in maintaining aortic homeostasis by several mechanisms, such as inhibiting inflammation and ECM degradation. In conclusion, this study provides evidence that loss of SOST activates Wnt/ β-catenin signaling, which regulates downstream genes important in maintaining aortic wall integrity. The findings have important implications for on-going trials of treatments to interfere with SOST in patients with osteoporosis.
